首页> 美国卫生研究院文献>Aging (Albany NY) >miR-375-3p suppresses tumorigenesis and partially reverses chemoresistance by targeting YAP1 and SP1 in colorectal cancer cells
【2h】

miR-375-3p suppresses tumorigenesis and partially reverses chemoresistance by targeting YAP1 and SP1 in colorectal cancer cells

机译:miR-375-3p通过靶向大肠癌细胞中的YAP1和SP1抑制肿瘤发生并部分逆转化学耐药性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Clinically, one of the principal factors in the failure of advanced colorectal cancer (CRC) treatment is chemoresistance to 5-fluorouracil (5FU)-based chemotherapy. Although microRNA-375-3p (miR-375) is considered a tumor suppressor in multiple cancers, the mechanism of miR-375 in the regulation of drug resistance in CRC remains unclear. In this study, we investigated the chemosensitivity of miR-375 to 5FU in CRC from biological and clinical aspects. We found that miR-375 was significantly downregulated in CRC tissues and cell lines, and low miR-375 expression was strongly correlated with poor overall survival in CRC patients. Overexpression of miR-375 sensitized CRC cells to a broad spectrum of chemotherapeutic drugs in vitro and in vivo. Further mechanistic analysis demonstrated that miR-375 enhanced CRC cell sensitivity to 5FU by directly targeting YAP1 and SP1. MiR-375 downregulated YAP1, resulting in reduced expression of the Hippo-YAP1 pathway downstream genes CTGF, cyclin D1 and BIRC5 (also known as survivin). Overall, miR-375 was confirmed as a prospective molecular biomarker in the chemoresistance and prognosis of CRC patients, and the synergy between miR-375 and chemotherapeutic drugs could be a promising therapeutic strategy for CRC patients, especially with chemoresistance.
机译:在临床上,晚期结直肠癌(CRC)治疗失败的主要因素之一是对基于5氟尿嘧啶(5FU)的化学疗法的化学耐药性。尽管microRNA-375-3p(miR-375)被认为是多种癌症的肿瘤抑制因子,但miR-375在CRC耐药性调节中的机制仍不清楚。在这项研究中,我们从生物学和临床方面研究了miR-375对CRC中5FU的化学敏感性。我们发现,在CRC组织和细胞系中miR-375显着下调,而miR-375的低表达与CRC患者的整体生存期差密切相关。在体外和体内,miR-375致敏的CRC细胞对多种化疗药物的过度表达。进一步的机理分析表明,miR-375通过直接靶向YAP1和SP1增强了CRC细胞对5FU的敏感性。 MiR-375下调YAP1,导致Hippo-YAP1途径下游基因CTGF,cyclin D1和BIRC5(也称为survivin)的表达降低。总体而言,miR-375被证实是CRC患者化学耐药性和预后的前瞻性分子生物标志物,miR-375与化学治疗药物之间的协同作用可能是CRC患者的有前途的治疗策略,尤其是化学耐药性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号